PDCD1 and neutropenia: This specifically includes neutropenia in the case of pembrolizumab and nivolumab that target programmed cell death protein 1 (PD-1) and ipilimumab that targets cytotoxic T-lymphocyte antigen 4 (CTLA-4) [42].